Interleukin-5 does not influence differential transcription of transmembrane and soluble isoforms of IL-5Rα in vivo

European Journal of Haematology

Volumn 77, Issue 3, 2006, Pages 181-190

  Byström, Jonas ^a,c   Dyer, Kimberly D ^a   Ravin, Suk See Ting De ^a   Naumann, Nora ^a   Stephany, David A ^a   Foster, Paul S ^b   Wynn, Thomas A ^a   Rosenberg, Helene F ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Granulocytes; Hematopoiesis; Interleukin 5

Indexed keywords

INTERLEUKIN 5; INTERLEUKIN 5 ALPHA RECEPTOR; INTERLEUKIN 5 RECEPTOR; ISOPROTEIN; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; EOSINOPHILIA; GENE DELETION; HELMINTHIASIS; IN VIVO STUDY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; SCHISTOSOMA MANSONI; SIGNAL TRANSDUCTION; SPECIES COMPARISON; TRANS SPLICING; TRANSCRIPTION REGULATION; WILD TYPE;

ALTERNATIVE SPLICING; ANIMALS; BASE SEQUENCE; BONE MARROW; DNA, COMPLEMENTARY; EOSINOPHILS; EXONS; INTERLEUKIN-5; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; PROTEIN ISOFORMS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-5; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCHISTOSOMIASIS MANSONI; SOLUBILITY; SPECIES SPECIFICITY; TRANSCRIPTION, GENETIC;

EID: 33746833673     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00699.x     Document Type: Article

References (43)

1. ROTHENBERG ME. Eosinophilia. N Engl J Med 1998;338:1592-1600.
2. FOSTER PS, MOULD AW, YANG M, et al. Elemental signals regulating eosinophil accumulation in the lung. Immunol Rev 2001;179:173-181.
3. ROBOZ GJ, RAFII S. Interleukin-5 and the regulation of eosinophil production. Curr Opin Hematol 1999;6:164-168.
4. KOTSIMBOS AT, HAMID Q. IL-5 and IL-5 receptor in asthma. Mem Inst Oswaldo Cruz 1997;92(Suppl. 2):75-91.
5. YAMAGUCHI N, HITOSHI Y, TAKAKI S, MURATA Y, MIGITA M, KAMIYA T, MINOWADA J, TOMINAGA A, TAKATSU K. Murine interleukin-5 receptor isolated by immunoaffinity chromatography: comparison of determined N-terminal sequence and deduced primary sequence from cDNA and implication of a role of the intracytoplasmic domain. Int Immunol 1991;3:889-898.
6. TAKAKI S, TOMINAGA A, HITOSHI Y, MITA S, SONODA E, YAMAGUCHI N, TAKATSU K. Molecular cloning and expression of the murine interleukin-5 receptor. EMBO J 1990;9:4367-4374.
7. IMAMURA F, TAKAKI S, AKAGI K, ANDO M, YAMAMURA K, TAKATSU K, TOMINAGA A. The murine interleukin-5 receptor alpha subunit gene: characterizaion of the gene structure and chromosome mapping. DNA Cell Biol 1994;13:283-292.
8. MURATA Y, TAKAKI S, MIGITA M, KIKUCHI Y, TOMINAGA A, TAKATSU K. Molecular cloning and expression of the human interleukin-5 receptor. J Exp Med 1992;175:341-351.
9. TAVERNIER J, DEVOS R, CORNELIS S, TUYPENS T, VAN DER HEYDEN J, FIERS W, PLAETINCK G. A human high affinity interleukin-5 receptor (IL5R) is composed of an IL-5-specific alpha chain and a beta chain shared with the receptor for GM-CSF. Cell 1991;66:1175-1184.
10. TUYPENS T, PLAETINCK G, BAKER E, SUTHERLAND G, BRUSSELLE G, FIERS W, DEVOS R, TAVERNIER J. Organization and chromosomal localization of the human interleukin-5 receptor alpha-chain gene. Eur Cytokine Netw 1992;3:451-459.
11. YOSHIDA T, IKUTA K, SUGAYA H, et al. Defective B-1 cell development and impaired immunity against Angiostrongylus cantonensis in IL-5R alpha-deficient mice. Immunity 1996;4:483-494.
12. SUGAYA H, AOKI M, YOSHIDA T, TAKATSU K, YOSHIMURA K. Eosinophilia and intracranial worm recovery in interleukin-5 transgenic and intereleukin-5 receptor alpha chainknockout mice infected with Aniogstrongylus cantonensis. Parasitol Res 1997;83:583-590.
13. HIROI T, YANAGITA M, IIJIMA H, IWATANI K, YOSHIDA T, TAKATSU K, KIYONO H. Deficiency of IL-5 receptor alpha chain selectively influences the development of the common mucosal immune system independent IgA-producing B-1 cell in mucosa-associated tissues. J Immunol 1999;162:821-828.
14. TAKAKI S, TOMINAGA A, HITOSHI Y, MITA S, SONODA E, YAMAGUCHI N, TAKATSU K. Molecular cloning and expression of the murine interleukin-5 receptor. EMBO J 1990;9:4367-4374.
15. TAVERNIER J, TUYPENS T, PLAETINCK G, VERHEE A, FIERS W, DEVOS R. Molecular basis of the membrane-anchored and two soluble isoforms of the human interleukin-5 receptor alpha subunit. Proc Natl Acad Sci USA 1992;89:7041-7045.
16. YASRUEL Z, HUMBERT M, KOTSIMBOS TC, et al. Membrane-bound and soluble alpha IL-5 receptor mRNA in the bronchial mucosa of atopic and nonatopic asthmatics. Am J Respir Crit Care Med 1997;155:1413-1418.
17. LINS C, BOROJEVIC R. Interleukin-5 receptor alpha chain expression and splicing during brain development in mice. Growth Factors 2001;19:145-152.
18. LIU LY, SEDGWICK JB, BATES ME, VRTIS RF, GERN JE, KITA H, JARJOUR NN, BUSSE WW, KELLY EA. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. J Immunol 2002;169:6452-6458.
19. GEVAERT P, BACHERT C, HOLTAPPELS G, NOVO CP, VAN DER HEYDEN J, FRANSEN L, DEPRAETERE S, WALTER H, VAN CAUWENBERGE P, TAVERNIER J. Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. Allergy 2003;58:371-379.
20. DEVOS R, GUISEZ Y, CORNELIS S, VERHEE A, VAN DER HEYDEN J, MANNEBERG M, LAHM HW, FIERS W, TAVERNIER J, PLAETINCK G. Recombinant soluble human interleukin-5 (hIL-5) receptor molecules. Cross-linking and stoichiometry of binding to IL-5. J Biol Chem 1993;268:6581-6587.
21. MONAHAN J, SIEGEL N, KEITH R, et al. Attenuation of IL-5-mediated signal transduction, eosinophil survival, and inflammatory mediator release by a soluble human IL-5 receptor. J Immunol 1997;159:4024-4034.
22. YAMAGUCHI S, NAGAI H, TANAKA H, TSUJIMOTO M, TSURUOKA N. Time course study for antigen-induced airway hyperreactivity and the effect of soluble IL-5 receptor. Life Sci 1994;54:PL471-PL475.
23. DEVOS R, GUISEZ Y, PLAETINCK G, CORNELIS S, TAVERNIER J, VAN DER HEYDEN J, FOLEY LH, SCHEFFLER JE. Covalent modification of the interleukin-5 receptor by isothiazolones leads to inhibition of the binding of interleukin-5. Eur J Biochem 1994;225:635-640.
24. BANKS M, GRABER P, PROUDFOOT AE, AROD CY, ALLET B, BERNARD AR, SEBILLE E, MCKINNON M, WELLS TN, SOLARI R. Soluble interleukin-5 receptor alphachain binding assays: use for screening and analysis of interleukin-5 mutants. Anal Biochem 1995;230:321-328.
25. DEVOS R, PLAETINCK G, CORNELIS S, GUISEZ Y, VAN DER HEYDEN J, TAVERNIER J. Interleukin-5 and is receptor: a drug target for eosinophilia associated with chronic allergic disease. J Leukoc Biol 1995;57:813-819.
26. NAGAI H, YAMAGUCHI S, TANAKA H. The role of interleukin-5 (IL-5) in allergic airway hyperresponsiveness in mice. Ann N Y Acad Sci 1996;796:91-96.
27. TAVERNIER J, VAN DER HEYDEN J, VERHEE A, BRUSSELLE G, VAN OSTADE X, VANDERKERCKHOVE J, NORTH J, RANKIN SM, KAY AB, ROBINSON DS. Interleukin-5 regulates the isoform expression of its own receptor alpha subunit. Blood 2000;95:1600-1607.
28. PEREZ C, VANDESOMPELE J, VANDENBROUCKE I, HOLTAPPELS G, SPELEMAN F, GEVAERT P, VAN CAUWENBERGE P, BACHERT C. Quantitative real time polymerase chain reaction for measurement of human interleukin-5 receptor alpha spliced isoforms mRNA. BMC Biotechnol 2003;3:17.
29. KOPF M, BROMBACHER F, HODGKIN PD, et al. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 1996;4:15-24.
30. YU C, CANTOR AB, YANG H, BROWNE C, WELLS RA, FUJIWARA Y, ORKIN SH. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med 2002;195:1387-1395.
31. SABIN EA, KOPF MA, PEARCE EJ. Schistosoma mansoni egg-induced early IL-4 production is dependent upon IL-5 and eosinophils. J Exp Med 1996;184:1871-1878.
32. ZHANG JQ, BIEDERMANN B, NITSCHKE L, CROCKER PR. The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur J Immunol 2004;34:1175-1184.
33. BYSTRÖM J, WYNN TA, DOMACHOWSKE JB, ROSENBERG HF. Gene microarray analysis reveals interleukin-5-dependent transcriptional targets in mouse bone marrow. Blood 2004;103:868-877.
34. LEE NA, MCGARRY MP, LARSON KA, HORTON MA, KRISTENSEN AB, LEE JJ. Expression of IL-5 in thymocytes/T cells leads to the development of a massive eosinophilia, extramedullary eosinophilopoiesis, and unique histopathologies. J Immunol 1997;158:1332-1344.
35. BAO S, BEAGLEY KW, MURRAY AM, CARISTO V, MATTHAEI KI, YOUNG IG, HUSBAND AJ. Intestinal IgA plasma cells of the B1 lineage are IL-5 dependent. Immunology 1998;94:181-188.
36. LACH-TRIFILIEFF E, MCKAY RA, MONIA BP, KARRAS JG, WALKER C. In vitro and in vivo inhibition of interleukin (IL)-5-mediated eosinopoiesis by murine IL-5Ralpha antisense oligonucleotide. Am J Respir Cell Mol Biol 2001;24:116-122.
37. KARRAS JG, MCKAY RA, DEAN NM, MONIA BP. Deletion of individual exons and induction of soluble murine interleukin-5 receptor-alpha chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing. Mol Pharmacol 2000;58:380-387.
38. KARRAS JG, MCKAY RA, LU T, DEAN NM, MONIA BP. Antisense inhibition of membrane-bound human interleukin-5 receptor alpha chain does not affect soluble receptor expression and induces apoptosis in TF-1 cells. Antisense Nucleic Acid Drug Dev 2000;10:347-357.
39. KARRAS JG, MAIER MA, LU T, WATT A, MANOHARAN M. Peptide nucleic acids are potent modulators of endogenous pre-mRNA splicing of the murine interleukin-6 receptor-alpha chain. Biochemistry 2001;40:7853-7859.
40. ZHANG J, KUVELKAR R, CHEEWATRAKOOLPONG B, WILLIAMS S, EGAN RW, BILLAH MM. Evidence for multiple promoters of the human IL-5 receptor alpha subunit gene: a novel 6-base pair element determines cell-specific promoter function. J Immunol 1997;159:5412-5421.
41. DASER A, KOETZ K, BATJER N, JUNG M, RUSCHENDORF F, GOLTZ M, ELLERBROK H, RENZ H, WALTER J, PAULSEN M. Genetics of atopy in a mouse model: polymorphism of the IL-5 receptor alpha chain. Immunogenetics 2000;51:632-638.
42. CHEONG HS, KIM LH, PARK BL, CHOI YH, PARK HS, HONG SJ, CHOI BW, PARK CS, SHIN HD. Association analysis of interleukin-5 receptor alpha subunit (IL5RA) polymorphisms and asthma. J Hum Genet 2005;50:628-634.
43. JANS DA, BRIGGS LJ, GUSTIN SE, JANS P, FORD S, YOUNG IG. The cytokine interleukin-5 (IL-5) effects cotransport of its receptor subunits to the nucleus in vitro. FEBS Lett 1997;410:368-372.